WallStreetZenWallStreetZen

NASDAQ: GLUE
Monte Rosa Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their GLUE stock forecasts and price targets.

Forecast return on equity

Is GLUE forecast to generate an efficient return?

Company
-24.59%
Industry
96.93%
Market
-62.31%
GLUE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GLUE forecast to generate an efficient return on assets?

Company
-17.21%
Industry
35.83%
GLUE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GLUE earnings per share forecast

What is GLUE's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.30-470.88%
Avg 2 year Forecast
-$1.08-1,450%
Avg 3 year Forecast
-$0.69-956.25%

GLUE revenue forecast

What is GLUE's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$124.1M-22.16%
Avg 2 year Forecast
$86.9M-45.53%
Avg 3 year Forecast
$163.1M+2.29%
GLUE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GLUE revenue growth forecast

How is GLUE forecast to perform vs Biotechnology companies and vs the US market?

Company
-4.95%
Industry
90.96%
Market
11.86%
GLUE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GLUE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GLUE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GLUE$10.05N/AN/A
MGTX$7.75$35.00+351.61%Strong Buy
SVRA$3.61$6.29+74.13%Buy
ZVRA$10.81$24.33+125.20%Strong Buy
OLMA$9.36$23.33+149.28%Strong Buy
View Top Biotech Stocks

Monte Rosa Therapeutics Stock Forecast FAQ

What is GLUE's earnings growth forecast for 2025-2027?

(NASDAQ: GLUE) Monte Rosa Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.01%.

Monte Rosa Therapeutics's earnings in 2025 is $6,153,000.On average, 3 Wall Street analysts forecast GLUE's earnings for 2025 to be -$18,249,964, with the lowest GLUE earnings forecast at -$27,064,321, and the highest GLUE earnings forecast at -$12,917,062. On average, 3 Wall Street analysts forecast GLUE's earnings for 2026 to be -$66,430,607, with the lowest GLUE earnings forecast at -$129,170,624, and the highest GLUE earnings forecast at $7,381,179.

In 2027, GLUE is forecast to generate -$42,134,227 in earnings, with the lowest earnings forecast at -$113,178,071 and the highest earnings forecast at $28,909,616.

If you're new to stock investing, here's how to buy Monte Rosa Therapeutics stock.

What is GLUE's revenue growth forecast for 2025-2027?

(NASDAQ: GLUE) Monte Rosa Therapeutics's forecast annual revenue growth rate of -4.95% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.86%.

Monte Rosa Therapeutics's revenue in 2025 is $159,487,000.On average, 3 Wall Street analysts forecast GLUE's revenue for 2025 to be $7,635,829,179, with the lowest GLUE revenue forecast at $7,265,540,057, and the highest GLUE revenue forecast at $7,825,894,526. On average, 3 Wall Street analysts forecast GLUE's revenue for 2026 to be $5,343,542,680, with the lowest GLUE revenue forecast at $738,117,852, and the highest GLUE revenue forecast at $11,739,149,338.

In 2027, GLUE is forecast to generate $10,034,404,649 in revenue, with the lowest revenue forecast at $2,460,392,840 and the highest revenue forecast at $17,608,416,458.

What is GLUE's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: GLUE) forecast ROA is -17.21%, which is lower than the forecast US Biotechnology industry average of 35.83%.

What is GLUE's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: GLUE) Monte Rosa Therapeutics's current Earnings Per Share (EPS) is $0.08. On average, analysts forecast that GLUE's EPS will be -$0.30 for 2025, with the lowest EPS forecast at -$0.44, and the highest EPS forecast at -$0.21. On average, analysts forecast that GLUE's EPS will be -$1.08 for 2026, with the lowest EPS forecast at -$2.10, and the highest EPS forecast at $0.12. In 2027, GLUE's EPS is forecast to hit -$0.69 (min: -$1.84, max: $0.47).

What is GLUE's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: GLUE) forecast ROE is -24.59%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.